Novel nonpharmacologic approaches for stroke prevention in atrial fbrillation: Results from clinical trials

Medical Devices: Evidence and Research

Volumn 8, Issue , 2015, Pages 103-114

  Proietti, Riccardo ^a,b   Joza, Jacqueline ^a   Arensi, Andrea ^b   Levi, Michael ^a   Russo, Vincenzo ^c   Tzikas, Apostolos ^d   Danna, Paolo ^b   Sagone, Antonio ^b   Viecca, Maurizio ^b   Essebag, Vidal ^a,e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF MILAN   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Interbalkan Medical Centre   (Greece)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Atrial fbrillation; CHADS; Left atrial appendage closure

Indexed keywords

CARDIOVASCULAR SURGERY; DRUG PRODUCTS; SURGERY; TRANSPLANTATION (SURGICAL);

ATRIAL FBRILLATION; CARDIAC ARRHYTHMIA; CHADS; INTERNATIONAL NORMALIZED RATIOS; LEFT ATRIAL APPENDAGE CLOSURE; LONG-TERM SOLUTIONS; RANDOMIZED CONTROLLED TRIAL; STAND-ALONE OPERATION;

DISEASES;

ACETYLSALICYLIC ACID; CLOPIDOGREL; VITAMIN K GROUP; WARFARIN;

AMPLATZER VASCULAR PLUG; ANTICOAGULANT THERAPY; ARTERIOVENOUS FISTULA; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DEVICE EMBOLIZATION; DEVICE FAILURE; DEVICE SAFETY; ENDOVASCULAR SURGERY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMOPERICARDIUM; HUMAN; INCIDENCE; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MEDICAL DEVICE COMPLICATION; PERICARDIAL EFFUSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUTURE DELIVERY DEVICE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84922206202     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S70672     Document Type: Article

References (70)

1. Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fbrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429.
2. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fbrillation. N Engl J Med. 2014;370(26):2478–2486.
3. Mohammed I, Mohmand-Borkowski A, Burke JF, Kowey PR. Stroke prevention in atrial fbrillation. J Cardiovasc Med (Hagerstown). 2012;13(2):73–85.
4. Contractor T, Khasnis A. Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation? Cardiol Res Pract. 2011;2011:752808.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146(12):857–867.
6. Leithäuser B, Park J W. Cardioembolic stroke in atrial fbrillation-rationale for preventive closure of the left atrial appendage. Korean Circ J. 2009;39(11):443–458.
7. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fbrillation (WASPO). Age Ageing. 2007;36(2):151–156.
8. Mant J, Hobbs FD, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fbrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.
9. Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fbrillation. N Engl J Med. 2009;360(20):2066–2078.
10. Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagula-tion for atrial fbrillation in the Atrial fbrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912.
11. Eikelboom J W, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fbrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372.
12. Patel MR, Mahaffey K W, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365(10):883–891.
13. Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365(11):981–992.
14. Giugliano R P, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2013;369(22):2093–2104.
15. Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis. 2011;31(3):310–320.
16. Kwong JS, Lam YY, Ya n B P, Yu CM. Bleeding of new oral anticoagulants for stroke prevention in atrial fbrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther. 2013;27(1):23–35.
17. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fbril-lation: executive summary. Eur Heart J. 2013;34(27):2094–2106.
18. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterolog y. 2013;145(1):105–112.
19. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fbrillation. Ann Thorac Surg. 1996;61(2):755–759.
20. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fbrillation. J Am Coll Cardiol. 2007;49(13):1490–1495.
21. Whitlock R P, Healey JS, Connolly SJ. Left atrial appendage occlusion does not eliminate the need for warfarin. Circulation. 2009;120(19):1927–1932.
22. Douglas YL, Jongbloed MR, Gittenberger-de Groot AC, et al. Histology of vascular myocardial wall of left atrial body after pulmonary venous incorporation. Am J Cardiol. 2006;97(5):662–670.
23. Di Biase L, Santangeli P, Anselmino M, et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fbrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60(6):531–538.
24. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999;82(5):547–554.
25. Narumiya T, Sakamaki T, Sato Y, Kanmatsuse K. Relationship between left atrial appendage function and left atrial thrombus in patients with nonvalvular chronic atrial fbrillation and atrial futter. Circ J. 2003;67(1):68–72.
26. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fbrillation. Stroke. 2007;38(2) (Suppl):624–630.
27. Bayard YL, Ostermayer SH, Hein R, et al. Percutaneous devices for stroke prevention. Cardiovasc Revasc Med. 2007;8(3):216–225.
28. Nakai T, Lesh MD, Gerstenfeld E P, Virmani R, Jones R, Lee RJ. Percutaneous left atrial appendage occlusion (PLAATO) for preventing cardioembolism: frst experience in canine model. Circulation. 2002;105(18):2217–2222.
29. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887–1889.
30. Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fbrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46(1):9–14.
31. Stöllberger C, Finsterer J, Schneider B. Does percutaneous closure of the left atrial appendage prevent stroke in atrial fbrillation? J Am Coll Cardiol. 4, 2006;47(7):1500.
32. Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of car-dioembolic stroke in non-anticoagulation eligible atrial fbrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6(2):220–226.
33. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fbrillation for anticoagulation: stroke risk stratifcation in patients taking aspirin. Circulation. 2004;110(16):2287–2292.
34. Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fbrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv. 2009;2(7):594–600.
35. Park JW, Leithäuser B, Gerk U, Vrsansky M, Jung F. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) for stroke prevention in atrial fbrillation: 2-year outcomes. J Invasive Cardiol. 2009;21(9):446–450.
36. Ussia G P, Mulè M, Cammalleri V, et al. Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fbrillation. Catheter Cardiovasc Interv. 2009;74(2):217–222.
37. Leal S, Moreno R, de Sousa Almeida M, Silva JA, Lopez-Sendon JL. Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fbrillation. Curr Cardiol Rev. 2012;8(1):37–42.
38. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fbrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–542.
39. Reddy VY, Doshi SK, Sievert H, et al; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fbrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013;127(6):720–729.
40. Bai R, Horton R P, DI Biase L, et al. Intraprocedural and long-term incomplete occlusion of the left atrial appendage following placement of the WATCHMAN device: a single center experience. J Cardiovasc Electrophysiol. 2012;23(5):455–461.
41. Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fbrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol. 2012;59(10):923–929.
42. Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fbrillation. J Am Coll Cardiol. 2013;61(17):1790–1798.
43. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fbrillation: an assessment of net clinical beneft. Eur Heart J. 2012;33(21):2700–2708.
44. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551–2556.
45. Maisel WH. Left atrial appendage occlusion – closure or just the beginning? N Engl J Med. 2009;360(25):2601–2603.
46. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fbrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12.
47. Park J W, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fbrillation: initial European experience. Catheter Cardiovasc Interv. 2011;77(5):700–706.
48. Lam Y Y, Yip G W, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fbrillation: initial Asia-Pacifc experience. Catheter Cardiovasc Interv. 2012;79(5):794–800.
49. Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and One-year Results in 35 Consecutive Patients After Closure of Left Atrial Appendage With the Amplatzer Cardiac Plug. Rev Esp Cardiol. 2013;66(2):90–97.
50. Urena M, Rodés-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fbrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol. 2013;62(2):96–102.
51. Munkholm-Larsen S, Cao C, Yan TD, Pehrson S, Dixen U. Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fbrillation: a systematic review. Heart. 2012;98(12):900–907.
52. Freixa X, Abualsaud A, Chan J, et al. Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™. Int J Cardiol. 2014;174(3):492–496.
53. Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model. Circ Cardiovasc Interv. 2010;3(3):224–229.
54. Fisher DC, Tunick PA, Kronzon I. Large gradient across a partially ligated left atrial appendage. J Am Soc Echocardiogr. 1998;11(12):1163–1165.
55. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol. 2000;36(2):468–471.
56. Benussi S, Mazzone P, Maccabelli G, et al. Thoracoscopic appendage exclusion with an atriclip device as a solo treatment for focal atrial tachycardia. Circulation. 2011;123(14):1575–1578.
57. Bruce CJ, Stanton CM, Asirvatham SJ, et al. Percutaneous epicardial left atrial appendage closure: intermediate-term results. J Cardiovasc Electrophysiol. 2011;22(1):64–70.
58. Friedman PA, Asirvatham SJ, Dalegrave C, et al. Percutaneous epicardial left atrial appendage closure: preliminary results of an electrogram guided approach. J Cardiovasc Electrophysiol. 2009;20(8):908–915.
59. Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm. 2011;8(2):188–193.
60. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013;62(2):108–118.
61. Stone D, Byrne T, Pershad A. Early Results With the LARIAT Device for Left Atrial Appendage Exclusion in Patients With Atrial Fibrillation at High Risk for Stroke and Anticoagulation. Catheter Cardiovasc Interv. 2013;n/a.
62. Han FT, Bartus K, Lakkireddy D, et al. The effects of LAA ligation on LAA electrical activity. Heart Rhythm. 2014;11(5):864–870.
63. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fbrillation: an update of the 2010 ESC Guidelines for the management of atrial fbrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
64. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. Epub March 28, 2014.
65. Cheng Y, McGregor J, Edmiston D, et al. Long-term safety and biocompatibility of the Coherex WaveCrest™ left atrial appendage occluder in a canine model. J Am Coll Cardiol. 2014;63: doi:10.1016/S0735–1097(14)61680–61686.
66. Cheng Y, McGregor J, Sommer R, et al. TCT-764 Safety and Biocompat-ibility of the Coherex WaveCrest™ Left Atrial Appendage Occluder in a 30-Day Canine Study. J Am Coll Cardiol. 2012;60(17_S): doi:10.1016/j.jacc.2012.08.807.
67. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123(4):417–424.
68. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122(2):109–118.
69. Stöllberger C, Schneider B, Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. Chest. 2003;124(6):2356–2362.
70. Meier B, Palacios I, Windecker S et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagula-tion in patients with atrial fbrillation. Catheter Cardiovasc Interv. 2003;60(3):417–422.